了解加拿大的药品特例准入计划（DEAPs）及其相关的社会和政治问题。
Understanding drug exceptional access programs (DEAPs) in Canada, and their associated social and political issues.
机构信息
Université de Montréal, Faculty of Pharmacy, 2940 Chem. de Polytechnique, Montréal, QC, H3T 1J4, Canada.
Faculty of Law (LL.M. Candidate), McGill University, 3644 Peel St, Montreal, QC, H3A 1W9, Canada.
出版信息
BMC Med Ethics. 2024 Mar 26;25(1):37. doi: 10.1186/s12910-024-01038-8.
Abstract
Drug exceptional access programs (DEAPs) exist across Canada to address gaps in access to pharmaceuticals. These programs circumvent standard procedures, raising epistemic, economic, social and political issues. This commentary provides insights into these issues by revealing the context and procedures on which these programs depend.
摘要
加拿大各地都有药物特批获取项目（DEAPs），旨在解决药品获取方面的差距问题。这些项目规避了标准程序，引发了认识论、经济、社会和政治方面的问题。本评论通过揭示这些项目所依赖的背景和程序，深入探讨了这些问题。
相似文献
1
Understanding drug exceptional access programs (DEAPs) in Canada, and their associated social and political issues.
BMC Med Ethics. 2024 Mar 26;25(1):37. doi: 10.1186/s12910-024-01038-8.
2
Drug reimbursement policies in Canada--need for improved access to critical therapies.
Ann Pharmacother. 2008 Jun;42(6):869-73. doi: 10.1345/aph.1K373. Epub 2008 May 13.
3
Provision of pharmaceuticals in Australian hospitals: equity of access?
Pharm World Sci. 2007 Apr;29(2):47-50. doi: 10.1007/s11096-006-9066-y. Epub 2006 Dec 6.
4
Global pharmaceutical development and access: critical issues of ethics and equity.
MEDICC Rev. 2011 Jul;13(3):16-22. doi: 10.37757/MR2011V13.N3.5.
5
Role of primary health care in ensuring access to medicines.
Croat Med J. 2010 Jun;51(3):181-90. doi: 10.3325/2010.51.181.
6
Social, political, commercial, and corporate determinants of rural health equity in Canada: an integrated framework.
Can J Public Health. 2022 Oct;113(5):749-754. doi: 10.17269/s41997-022-00630-y. Epub 2022 Apr 18.
7
Paces of Costly Care: Rare Disease Drug Access in Canada.
Med Anthropol. 2020 May-Jun;39(4):319-332. doi: 10.1080/01459740.2019.1573229. Epub 2019 Mar 20.
8
Access to new drugs for dialysis patients: challenges for indigenous and non-indigenous populations.
Clin Nephrol. 2010 Nov;74 Suppl 1:S138-41. doi: 10.5414/cnp74s138.
9
Why equity in health and in access to health care are elusive: Insights from Canada and South Africa.
Glob Public Health. 2018 Nov;13(11):1533-1557. doi: 10.1080/17441692.2017.1407813. Epub 2017 Dec 4.
10
Drug shortage registry under discussion.
CMAJ. 2011 Jul 12;183(10):E637-8. doi: 10.1503/cmaj.109-3904. Epub 2011 May 30.
本文引用的文献
1
Prevalence and nature of manufacturer-sponsored patient support programs for prescription drugs in Canada: a cross-sectional study.
CMAJ. 2023 Nov 26;195(46):E1565-E1576. doi: 10.1503/cmaj.230841.
2
[Not Available].
CMAJ. 2023 Sep 18;195(36):E1245-E1247. doi: 10.1503/cmaj.230246-f.
3
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.
Curr Oncol. 2022 Dec 16;29(12):9891-9895. doi: 10.3390/curroncol29120778.
4
Reforms to the patented medicine prices review board and the introduction of new drugs in Canada: An observational study.
Health Policy. 2022 Oct;126(10):1018-1022. doi: 10.1016/j.healthpol.2022.08.006. Epub 2022 Aug 10.
5
Strategies of stratification: Regulating market access in the era of personalized medicine.
Soc Stud Sci. 2021 Aug;51(4):628-653. doi: 10.1177/03063127211005539. Epub 2021 Apr 22.
6
Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs.
PLoS One. 2020 Jun 24;15(6):e0235021. doi: 10.1371/journal.pone.0235021. eCollection 2020.
7
[Three types of brand name loyalty strategies set up by drug manufacturers].
Healthc Policy. 2014 Nov;10(2):79-89.
8
Niche markets and evidence assessment in transition: a critical review of proposed drug reforms.
Med Law Rev. 2014 Spring;22(2):200-20. doi: 10.1093/medlaw/fwu005.
9
Bye, bye blockbusters, hello niche busters.
CMAJ. 2011 Aug 9;183(11):E697-8. doi: 10.1503/cmaj.109-3874. Epub 2011 Jun 20.
10
Access to drugs for cancer: Does where you live matter?
Can J Public Health. 2005 Nov-Dec;96(6):454-8. doi: 10.1007/BF03405189.
Zotero 插件